Morgan Stanley (NYSE:MS) analyst David Lewis maintained a Buy rating on Boston Scientific Corp (NYSE:BSX). on Wednesday, setting a price target of $40, which is approximately 14.19% above the present share price of $35.03.
Lewis expects Boston Scientific Corp. to post earnings per share (EPS) of -$0.12 for the fourth quarter of 2020.
The current consensus among 15 TipRanks analysts is for a Strong Buy rating of shares in Boston Scientific, with an average price target of $43.73.
The analysts price targets range from a high of $48 to a low of $40.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.66 billion and a net profit of $282 million. The company's market cap is $50.16 billion.
According to TipRanks.com, Morgan Stanley analyst David Lewis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.8% and a 73.89% success rate.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.